These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 30689515)
41. Expression of a C terminally truncated form of pertussis toxin S1 subunit effectively induces protection against pertussis toxin following DNA-based immunization. Kamachi K; Arakawa Y Infect Immun; 2004 Jul; 72(7):4293-6. PubMed ID: 15213178 [TBL] [Abstract][Full Text] [Related]
42. Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro. Wilson AD; Morgan AJ J Virol; 2002 May; 76(10):5071-81. PubMed ID: 11967323 [TBL] [Abstract][Full Text] [Related]
43. Induction of CD4(+) and CD8(+) Bordetella pertussis toxin subunit S1 specific T cells by immunization with synthetic peptides. Fagerberg J; Askelöf P; Wigzell H; Mellstedt H Cell Immunol; 1999 Sep; 196(2):110-21. PubMed ID: 10527563 [TBL] [Abstract][Full Text] [Related]
44. Stimulation of T-Cell activation by CXCL12/stromal cell derived factor-1 involves a G-protein mediated signaling pathway. Nanki T; Lipsky PE Cell Immunol; 2001 Dec; 214(2):145-54. PubMed ID: 12088413 [TBL] [Abstract][Full Text] [Related]
45. Immunogenicity of a three-component acellular pertussis vaccine administered at birth. Belloni C; De Silvestri A; Tinelli C; Avanzini MA; Marconi M; Strano F; Rondini G; Chirico G Pediatrics; 2003 May; 111(5 Pt 1):1042-5. PubMed ID: 12728086 [TBL] [Abstract][Full Text] [Related]
48. Specific immune response in adult medical personnel immunized with acellular pertussis vaccine with special emphasis on T helper cell response. Lin TY; Chiang BL Vaccine; 1997 Dec; 15(17-18):1917-21. PubMed ID: 9413102 [TBL] [Abstract][Full Text] [Related]
49. Proliferative responses to purified and fractionated Bordetella pertussis antigens in mice immunized with whole-cell pertussis vaccine. Petersen JW; Andersen P; Ibsen PH; Capiau C; Wachmann CH; Hasløv K; Heron I Vaccine; 1993; 11(4):463-72. PubMed ID: 8470432 [TBL] [Abstract][Full Text] [Related]
50. Neonatal human autologous dendritic cells pulsed with recombinant protein antigen prime the generation of non-polarized CD4 T-cell effectors. Matthews NC; Power UF; Reen DJ Int Immunol; 2007 Jun; 19(6):703-12. PubMed ID: 17493958 [TBL] [Abstract][Full Text] [Related]
51. Characterization of Individual Human Antibodies That Bind Pertussis Toxin Stimulated by Acellular Immunization. Acquaye-Seedah E; Reczek EE; Russell HH; DiVenere AM; Sandman SO; Collins JH; Stein CA; Whitehead TA; Maynard JA Infect Immun; 2018 Jun; 86(6):. PubMed ID: 29581192 [TBL] [Abstract][Full Text] [Related]
52. Mutants of pertussis toxin suitable for vaccine development. Pizza M; Covacci A; Bartoloni A; Perugini M; Nencioni L; De Magistris MT; Villa L; Nucci D; Manetti R; Bugnoli M Science; 1989 Oct; 246(4929):497-500. PubMed ID: 2683073 [TBL] [Abstract][Full Text] [Related]
53. Immunization with whole cell but not acellular pertussis vaccines primes CD4 T Wilk MM; Borkner L; Misiak A; Curham L; Allen AC; Mills KHG Emerg Microbes Infect; 2019; 8(1):169-185. PubMed ID: 30866771 [TBL] [Abstract][Full Text] [Related]
54. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection. Matheson AJ; Goa KL Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466 [TBL] [Abstract][Full Text] [Related]
55. Immunogenicity and reactogenicity of the component acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous haemagglutinin. Kimura M; Kuno-Sakai H; Kamiya H; Ueda K; Isomura S; Koike M; Kato T; Ozaki T; Hirose M; Egami T Acta Paediatr Jpn; 1995 Oct; 37(5):562-74. PubMed ID: 8533580 [TBL] [Abstract][Full Text] [Related]
56. Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial. Wood N; Nolan T; Marshall H; Richmond P; Gibbs E; Perrett K; McIntyre P JAMA Pediatr; 2018 Nov; 172(11):1045-1052. PubMed ID: 30208475 [TBL] [Abstract][Full Text] [Related]
57. Calibration of pertussis toxin BRP batch 1 in a standardised CHO cell-based clustering assay. Markey K; Douglas-Bardsley A; Hockley J; Le Tallec D; Costanzo A Pharmeur Bio Sci Notes; 2018; 2018():112-123. PubMed ID: 30272557 [TBL] [Abstract][Full Text] [Related]
58. Role of pertussigen (pertussis toxin) on the mouse protective activity of vaccines made from Bordetella species. Munoz JJ; Peacock MG Microbiol Immunol; 1989; 33(4):341-55. PubMed ID: 2549344 [TBL] [Abstract][Full Text] [Related]
59. Antibody Specificity Following a Recent Raeven RHM; van der Maas L; Pennings JLA; Fuursted K; Jørgensen CS; van Riet E; Metz B; Kersten GFA; Dalby T Front Immunol; 2019; 10():1364. PubMed ID: 31275314 [No Abstract] [Full Text] [Related]
60. Acellular pertussis vaccine in children with perinatal human immunodeficiency virus-type 1 infection. de Martino M; Podda A; Galli L; Sinangil F; Mannelli F; Rossi ME; Vierucci A Vaccine; 1997 Aug; 15(11):1235-8. PubMed ID: 9286049 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]